CYTOF · CIK 0001601936
Altamira Therapeutics Ltd.
Annual figures as reported, FY2014–FY2024. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
CHF 379
▼ −99.9% vs FY2022
Net income
CHF 3.9M
▼ −85.4% vs FY2022
Diluted EPS
−CHF 7.88
▲ +98.6% vs FY2022
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginOperating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedNet income CAGR
−22.1%
3y
−19.6%
5y
Share count change (split-adjusted)
+22139.5%
5y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | ROE | ROA | Current ratio | Debt / equity | DPS |
|---|---|---|---|---|---|---|---|---|
| FY2024 | — | — | — | — | — | — | — | — |
| FY2023 | −8862.3% | −1560976.0% | 1020890.0% | 59.9% | 50.3% | 1.38× | — | CHF 4.00 |
| FY2022 | −372.4% | −5894.3% | 8680.3% | — | 420.9% | 0.14× | — | — |
| FY2021 | −3407.3% | −10756.3% | 26703.1% | 130.9% | 89.0% | 0.84× | — | — |
| FY2020 | — | — | — | 48.9% | 39.4% | 3.83× | 0.03× | — |
| FY2019 | — | — | — | 109.9% | 71.9% | 1.04× | — | — |
| FY2018 | — | — | — | 315.0% | 116.4% | 1.33× | 0.39× | — |
| FY2017 | — | — | — | — | −136.9% | 1.52× | — | — |
| FY2016 | — | — | — | −216.8% | −86.0% | 3.76× | — | — |
| FY2015 | — | — | — | −66.4% | — | — | — | — |
| FY2014 | — | — | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | — | — | — | — | — | — | — | — | — | — | — | — |
| FY2023 | CHF 379 | −CHF 34K | −CHF 5.9M | CHF 3.9M | −CHF 7.88 | — | — | CHF 7.7M | CHF 1.2M | CHF 6.5M | CHF 617K | — |
| FY2022 | CHF 306K | −CHF 1.1M | −CHF 18.0M | CHF 26.5M | −CHF 582.58 | — | — | CHF 6.3M | CHF 14.6M | −CHF 8.3M | CHF 15K | CHF 6.1M |
| FY2021 | CHF 64K | −CHF 2.2M | −CHF 6.9M | CHF 17.1M | −CHF 515.11 | — | — | CHF 19.2M | CHF 6.1M | CHF 13.0M | CHF 984K | — |
| FY2020 | — | — | −CHF 5.3M | CHF 8.2M | −CHF 505.40 | — | — | CHF 20.8M | CHF 4.0M | CHF 16.8M | CHF 11.3M | CHF 524K |
| FY2019 | — | — | −CHF 7.3M | CHF 6.6M | — | — | — | CHF 9.2M | CHF 3.2M | CHF 6.0M | CHF 1.4M | — |
| FY2018 | — | — | −CHF 11.0M | CHF 11.5M | — | — | — | CHF 9.9M | CHF 6.2M | CHF 3.6M | CHF 5.4M | CHF 1.4M |
| FY2017 | — | — | −CHF 24.4M | −CHF 24.4M | — | — | — | CHF 17.8M | CHF 20.0M | −CHF 2.2M | CHF 15.0M | — |
| FY2016 | — | — | −CHF 30.2M | −CHF 30.7M | — | — | — | CHF 35.7M | CHF 21.5M | CHF 14.1M | CHF 32.4M | — |
| FY2015 | — | — | −CHF 30.9M | −CHF 29.7M | — | — | — | — | — | CHF 44.7M | CHF 50.2M | — |
| FY2014 | — | — | — | — | — | — | — | — | — | CHF 53.3M | CHF 56.9M | — |
Latest filings
the most recent regulatory filings15-12GFORM 15-12B2026-02-27 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2025-08-29 ↗25-NSEDelisting notice2025-06-17 ↗6-KForeign issuer report2025-06-11 ↗SCHEDULE 13G/ASEC filing2025-05-15 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2025-05-09 ↗SCHEDULE 13D/ASEC filing2025-05-06 ↗20-FANNUAL REPORT2025-04-30 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2025-04-30 ↗S-8REGISTRATION STATEMENT2025-04-04 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.